

CURRICULUM VITAE

HEFEI WEN

APRIL 2024

CONTACT INFORMATION

Harvard Medical School & Harvard Pilgrim Health Care Institute
Department of Population Medicine, Division of Health Policy & Insurance Research
401 Park Drive, Suite 401 East
Boston MA 02215
Phone: (617) 867-4926
Email: hefei_wen@hphci.harvard.edu

ACADEMIC APPOINTMENTS

2021~Present Assistant Professor of Population Medicine,
Harvard Medical School
2019~Present Faculty Member, Department of Population Medicine,
Harvard Pilgrim Health Care Institute
2015~2019 Assistant Professor, Department of Health Management & Policy,
University of Kentucky College of Public Health

EDUCATION

2015 Ph.D., Health Services Research & Health Policy, Emory University
2008 B.A., *magna cum laude*, Economics, Peking University

HONORS & AWARDS

2022 [Harvard Medical School Excellent in Mentoring Award \(Nomination\)](#)
2020 [Harvard Medical School Eleanor & Miles Shore Faculty Award](#)
2020 [Best of AcademyHealth Annual Research Meeting](#)
2018 [AUPHA John D. Thompson Prize](#)
2018 [Best of AcademyHealth Annual Research Meeting](#)
2017 [Delta Omega Honorary Public Health Society \(Beta Gamma Chapter\)](#)
2015 [Best of AcademyHealth Annual Research Meeting](#)

PUBLICATIONS

PEER-REVIEWED JOURNAL ARTICLES

1. JR Cummings, **H Wen**, BG Druss. (2011). "Racial/Ethnic Differences in Treatment for Substance Use Disorders among U.S. Adolescents." [*Journal of the American Academy of Child & Adolescent Psychiatry*](#). 50(12): 1265-1274.
2. **H Wen**, JR Cummings, JM Hockenberry, LM Gaydos, BG Druss. (2013). "State Parity Laws and Access to Treatment for Substance Use Disorder in the United States: Implications for Federal Parity Legislation." [*JAMA Psychiatry*](#). 70(12): 1355-1362.
 - ❖ Cited in [*The White House*](#) Mental Health & Substance Use Disorder Parity Task Force Report [*HHS Report*](#) "Continuing Progress on the Opioid Epidemic: The Role of Affordable Care Act." [*The National Academies of Sciences, Engineering, & Medicine*](#) "Psychosocial Interventions for Mental and Substance Use Disorders."
3. JR Cummings, **H Wen**, M Ko, BG Druss. (2013). "Geography and Medicaid Mental Health Care Infrastructure." [*JAMA Psychiatry*](#). 70(10): 1084-1090.
4. JR Cummings, **H Wen**, M Ko, BG Druss. (2014). "Race/Ethnicity and Geographic Access to Medicaid Substance Use Disorder Treatment Facilities in the United States." [*JAMA Psychiatry*](#). 71(2): 190-196.
5. JR Cummings, **H Wen**, A Ritvo, BG Druss. (2014). "Health Insurance Coverage and Receipt of Specialty Treatment for Substance Use Disorders among U.S. Adults." [*Psychiatric Services*](#). 65(8): 1070-1073.
6. **H Wen**, BG Druss, JR Cummings. (2015). "Effect of Medicaid Expansions on Health Coverage and Access to Care among Low-Income Adults with Behavioral Health Conditions." [*Health Services Research*](#). 50(6): 1787-1809.
 - ❖ Awarded "[*Best of AcademyHealth*](#) 2015 Annual Research Meeting"
 - ❖ Cited in [*The White House*](#) "Making Health Care Better" Series on Mental Health [*The Surgeon General's Report*](#) "Facing Addiction in America." [*HHS Report*](#) "Benefits of Medicaid Expansion for Behavioral Health."
7. **H Wen**, JM Hockenberry, JR Cummings. (2015). "The Effect of Medical Marijuana Laws on Adolescent and Adult Use of Marijuana, Alcohol, and Other Substances." [*Journal of Health Economics*](#). 42: 64-80.
 - ❖ Top 10 most downloaded *JHE* article in 2015.
 - ❖ Featured in [*The Economist*](#), [*PBS NewsHour*](#), [*Vox*](#), [*NBER Digest*](#)
8. **H Wen**, TF Borders, BG Druss. (2016). "Number of Medicaid Prescriptions Grew and Spending Was Steady in Medicaid Expansion States." [*Health Affairs*](#). 35(9): 1604-1607.
9. JR Cummings, **H Wen**, M Ko. (2016). "Decline in Public Substance Use Disorder Treatment Centers Most Serious in Counties with High Shares of Black Residents." [*Health Affairs*](#). 35(6): 1036-1044.
10. **H Wen**, JM Hockenberry, JR Cummings. (2017). "Effect of Medicaid Expansion on Crime Reduction: Evidence from HIFA-Waiver Expansions." [*Journal of Public Economics*](#). 154: 67-94.

- ❖ Featured in [MSNBC](#), [NBER Bulletin](#)
- 11. **H Wen**, BR Schackman, B Aden, Y Bao. (2017). “States with Prescription Drug Monitoring Mandates Saw a Reduction of Opioids Prescribed to Medicaid Enrollees.” [Health Affairs](#). 36(4): 733-741.
 - ❖ Featured in [New York Times](#), [Bloomberg Editorials](#)
 - ❖ Cited in [The National Academies of Sciences, Engineering, & Medicine](#) “Pain Management and the Opioid Epidemic.”
- 12. **H Wen**, JM Hockenberry, TF Borders, BG Druss. (2017). “Impact of Medicaid Expansion on Medicaid-Covered Utilization of Buprenorphine for Opioid Use Disorder Treatment.” [Medical Care](#). 55(4): 336-341.
 - ❖ Featured in [The Economist](#)
 - ❖ Cited in [The National Academies of Sciences, Engineering, & Medicine](#) “Medications for Opioid Use Disorder Save Lives.”
- 13. **H Wen**, JM Hockenberry. (2018). “Association of Medical and Adult-Use Marijuana Laws with Opioid Prescribing for Medicaid Enrollees.” [JAMA Internal Medicine](#). 178(5): 673-679.
 - ❖ [Editorial Commentary](#), 5th most talked about *JAMA Intern Med* article in 2018.
 - ❖ Featured in [Washington Post](#), [NPR](#), [CNN](#), [NBC](#), [CBS](#), [Forbes](#), [Rolling Stone](#), [The Guardian](#)
- 14. **H Wen**, JM Hockenberry, HA Pollack. (2018). “Association of Buprenorphine-Waivered Physician Supply with Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.” [JAMA Network Open](#). 1(5):e182943.
- 15. KJ Johnston, **H Wen**, JM Hockenberry, KE Joynt Maddox. (2018). “Association between Patient Cognitive and Functional Status and Medicare Total Annual Cost of Care: Implications for Value-Based Payment.” [JAMA Internal Medicine](#). 178(11):1489-1497.
 - ❖ [Editorial Commentary](#)
- 16. **H Wen**, TF Borders, JR Cummings. (2019). “Trends in Buprenorphine Prescriptions by Physician Specialty.” [Health Affairs](#). 38(1): 24-28.
 - ❖ [Editorial Commentary](#)
- 17. **H Wen**, B Saloner, JR Cummings. (2019). “Behavioral and Other Chronic Health Conditions Among Adult Medicaid Enrollees: Implications for Work Requirements.” [Health Affairs](#). 38(4): 660-667.
 - ❖ Featured in [Reuters](#)
- 18. **H Wen**, JM Hockenberry, PJ Jeng, Y Bao. (2019). “Prescription Drug Monitoring Program Mandates: Impact on Opioid Prescribing and Related Hospital Use in Medicaid.” [Health Affairs](#). 38(9): 1550-1556.
- 19. **H Wen**, KJ Johnston, L Allen, TM Waters. (2019). “Medicaid Expansion Associated with Reductions in Preventable Hospitalizations.” [Health Affairs](#). 38(11): 1845-1849.
 - ❖ Awarded “[Best of AcademyHealth](#) 2018 Annual Research Meeting”
 - ❖ Feature in [Forbes](#)
 - ❖ Cited in [The National Academies of Sciences, Engineering, & Medicine](#) “Leading Health Indicators 2030: Advancing Health, Equity, and Well-Being.”

20. **H Wen**, AS Wilk, BG Druss, JR Cummings. (2019). "Medicaid Acceptance by Psychiatrists Before and After Medicaid Expansion." [*JAMA Psychiatry*](#). 76(9): 981-983.
 - ❖ Featured in [*Reuters*](#), [*Kaiser Health News*](#)
21. **H Wen**, JM Hockenberry, BG Druss. (2019). "The Effect of Medical Marijuana Laws on Marijuana-Related Attitude and Perception among US Adolescents and Young Adults." [*Prevention Science*](#). 20(2):215-223. Invited Special Issue Submission.
 - ❖ [*Editorial Commentary*](#)
22. KJ Johnston, **H Wen**, KE Joynt Maddox. (2019). "Why Do Rural Medicare Beneficiaries with Complex Chronic Conditions Have Higher Rates of Preventable Hospitalization and Mortality than Urban Beneficiaries?" [*Health Affairs*](#). 38(12): 1993-2002.
23. KJ Johnston, **H Wen**, M Schootman, KE Joynt Maddox. (2019). "Association of Patient Social, Cognitive, and Functional Risk Factors with Preventable Hospitalizations: Implications for Physician Value-Based Payment." [*Journal of General Internal Medicine*](#). 34(8): 1645-1652.
24. **H Wen**, A Soni, A Hollingsworth, S Freedman, JA Benitez, K Simon, B Saloner. (2020). "Association between Medicaid Expansion and Rates of Opioid-Related Hospital Use." [*JAMA Internal Medicine*](#). 180(5): 753-759.
 - ❖ Featured in [*Kaiser Health News*](#)
25. **H Wen**, BG Druss, B Saloner. (2020). "Self-Help Groups and Medication Use in Opioid Addiction Treatment: A National Analysis." [*Health Affairs*](#). 39(5): 740-746.
 - ❖ [*Editorial Commentary*](#), [*Health Affairs Forefront*](#)
 - ❖ Featured in [*Kaiser Health News*](#)
26. **H Wen**, ML Barnett, B Saloner. (2020). "Clinical Risk Factors for COVID-19 Among People with Substance Use Disorders." [*Psychiatric Services*](#). 71(12): 1308-1308.
27. KJ Johnston, **H Wen**, KE Joynt Maddox. (2020). "Relationship of a Claims-Based Frailty Index to Annualized Medicare Costs: A Cohort Study." [*Annals of Internal Medicine*](#). 172(8): 533-540.
 - ❖ [*Editorial Commentary*](#)
 - ❖ Awarded "[*Best of AcademyHealth*](#) 2020 Annual Research Meeting"
28. KJ Johnston, **H Wen**, KE Joynt Maddox. (2020). "Inadequate Risk Adjustment Impacts Geriatricians' Performance on Medicare Cost and Quality Measures." [*Journal of the American Geriatrics Society*](#). 68(2): 297-304.
 - ❖ [*Editorial Commentary*](#)
29. H Zhang, S Tallavajhala, SN Kapadia, PJ Jeng, Y Shi, **H Wen**, Y Bao. (2020). "State Opioid Limits and Volume of Opioid Prescriptions Received by Medicaid Patients." [*Medical Care*](#). 58(12): 1111-1115.
30. KJ Johnston, **H Wen**, KE Joynt Maddox, HA Pollack. (2021). "Ambulatory Care Access and Emergency Department Use for Medicare Beneficiaries with and without Disabilities." [*Health Affairs*](#). 40(6): 910-919.

31. KJ Johnston, **H Wen**, A Kotwal, KE Joynt Maddox. (2021). “Comparing Preventable Acute Care Use of Rural Versus Urban Americans: An Observational Study of National Rates During 2008-2017.” [*Journal of General Internal Medicine*](#). 36(12): 3728-3736.
32. JC Maclean, **H Wen**, K Simon, B Saloner. (2021). “Institutions for Mental Disease Waivers: Impact on Payments for Substance Use Treatment Facilities.” [*Health Affairs*](#). 40(2): 326-333.
33. J Wen, ***H Wen**, JS Butler, JC Talbert. (2021) “Impact of Medical and Recreational Marijuana Laws on Opioid Prescribing in Employer-Sponsored Health Insurance.” [*Health Economics*](#). 30(5): 989-1000.
* Corresponding author, mentee first author
34. C Drake, J Wen, J Hinde, ***H Wen**. (2021) “Impact of Medical and Recreational Marijuana Laws on Opioid Prescribing in Employer-Sponsored Health Insurance.” [*Health Economics*](#). 30(10): 2595-2605.
* Senior author
35. X Ji, JR Cummings, AC Mertens, **H Wen**, KE Effinger. (2021). “Substance Use, Substance Use Disorders, and Treatment in Adolescent and Young Adult Cancer Survivors: Results from a National Survey.” [*Cancer*](#). 127(17): 3223-3231.
❖ [*Editorial Commentary*](#)
36. AS Wilk, AJ Chen, **H Wen**, JR Cummings. (2022). “Recent Trends in School-based Mental Health Services Among Low-Income and Racial/Ethnic Minority Adolescents.” [*JAMA Pediatrics*](#). 176(8): 813-815.
37. KJ Johnston, **H Wen**, HA Pollack. (2022). “A Comparison of Ambulatory Care Access and Quality for Beneficiaries with Disabilities Covered by Medicare Advantage vs Traditional Medicare Insurance.” [*JAMA Health Forum*](#). 3(1): e214562.
38. Y Ma, KJ Johnston, H Yu, JF Wharam, ***H Wen**. (2022) “State Mandatory Paid Sick Leave Associated with a Decline in Emergency Department Use.” [*Health Affairs*](#). 41(8): 1169-1175.
* Corresponding/senior author, mentee first author
❖ Featured in [*A Health Podyssey*](#), [*The Nation*](#), [*Pew Trusts*](#)
39. JM Hockenberry, **H Wen**, BG Druss, T Loux, KJ Johnston. (2023). “No Improvement in Mental Health Treatment or Patient-Reported Outcomes at Medicare ACOs for Depression and Anxiety.” [*Health Affairs*](#). 42(11): 1478-1487.
❖ [*Editorial Commentary*](#), Editor’s pick of the top 10 article in 2023
❖ Featured in [*Fortune*](#)
40. Y Bao, H Zhang, E Bruera, R Portenoy, WE Rosa, MC Reid, ***H Wen**. (2023). “Medical Marijuana Legalization and Opioid- and Pain-related Outcomes among Patients Newly Diagnosed with Cancer.” [*JAMA Oncology*](#). 9(2): 206-214.
* Senior author
41. B Shuey, F Zhang, E Rosen, B Goh, N Trad, JF Wharam, ***H Wen**. (2023). “Massachusetts’ Opioid Limit Law Associated with a Reduction in Post-Operative Opioid Duration Among Orthopedic Patients.” [*Health Affairs Scholar*](#). 1(6): qxad068.
* Senior author, mentee first author

42. B Shuey, KJ Suda, A Halbisen, **H Wen**, JF Wharam, A Rosland, JM Liebschutz. (2024). “Antihypertensive Medication Use among People with and without Substance Use Disorders.” [*Journal of General Internal Medicine*](#). Online First.
43. B Shuey, A Halbisen, M Lakoma, F Zhang, S Argetsinger, EC Williams, BG Druss, ***H Wen**, JF Wharam. (2024). “National Trends in High-Acuity Alcohol-Related Complications During the COVID-19 Pandemic.” [*JAMA Health Forum*](#). 5(4): e240501.
* Co-senior author, mentee first author
❖ Featured in [*New York Times*](#), [*CNN*](#), [*CBS*](#)
44. **H Wen**, A Halbisen, KJ Johnston, BG Druss. (2024). “Rural and Urban Trends in U.S. Mental Health Readmissions.” [*JAMA Psychiatry*](#). Accepted.

OPINION ARTICLES & POLICY BRIEFS

45. JR Cummings, **H Wen**, BG Druss. (2013). “Improving Access to Mental Health Services for Youth in the United States.” [*JAMA*](#). 309(6): 553-554.
46. TF Borders, **H Wen**. (2018). “Illicit Drug and Opioid Use Disorders among Non-Metropolitan Residents Nationally.” [*Rural and Underserved Health Research Center Policy Briefs*](#). Jan 2018.
47. TF Borders, **H Wen**. (2018). “Perceived Treatment Need and Utilization for Illicit Drug and Opioid Use Disorders in Non-Metropolitan Areas.” [*Rural and Underserved Health Research Center Policy Briefs*](#). Jan 2018.
48. E Golberstein, **H Wen**, BF Miller. (2020). “Coronavirus Disease 2019 (COVID-19) and Mental Health for Children and Adolescents.” [*JAMA Pediatrics*](#). 174(9): 819-820.
❖ Featured in [*Washington Post*](#), [*TIME*](#), [*CNN*](#), [*BBC*](#), [*ABC*](#), [*Forbes*](#)
49. MA Burke, KG Carman, R Sullivan, **H Wen**, JF Wharam, H Yu. (2021). “Who Gets Medication-Assisted Treatment for Opioid Use Disorder, and Does It Reduce Overdose Risk? Evidence from the Rhode Island All-payer Claims Database.” [*Fed In Print*](#). Feb 2021.
50. MA Burke, KG Carman, R Sullivan, **H Wen**, JF Wharam, H Yu. (2021). “Did the Affordable Care Act Affect Access to Medications for Opioid Use Disorder among the Already Insured? Evidence from the Rhode Island All-payer Claims Database.” [*Fed In Print*](#). Oct 2021.
51. HA Pollack, KJ Johnston, **H Wen**. (2021) Americans with Disabilities Are a Health Disparity Population That Deserves Greater Attention and Resources.” [*Milbank Quarterly Opinion*](#). Jul 2021.
52. MA Burke, KG Carman, R Sullivan, **H Wen**, JF Wharam, H Yu. (2022). “Employment Trajectories among Individuals with Opioid Use Disorder: Can Evidence-Based Treatment Improve Outcomes?” [*Fed In Print*](#). Oct 2022.

BOOK CHAPTERS

- H Wen**, P Hung, X Ji, S Li. “China’s Health System.” in BJ Fried & LM Gaydos eds. [*World Health System: Challenges and Perspective*](#). Health Administration Press, 2012.

GRANT FUNDING

CURRENT FUNDING

2022~2026: *Impact of Medicare Part D Opioid Safety Policies on Disabled Beneficiaries Before and During the COVID-19 Pandemic*

by National Institute on Drug Abuse (R01DA055131): **\$2,606,194**

Principal Investigator: 40%

- ❖ This project will examine beneficial and detrimental effects of Medicare opioid safety edits policy implementation on disabled beneficiaries who are prescribed long-term opioid therapy and compare the racial/ethnic and rural-urban differences in beneficial and detrimental policy effects.

2022~2026: *Impact of High Deductible Health Plans and COVID-19 on Alcohol Use Disorder Treatment Access, Outcomes, and Disparities?*

by National Institute on Alcohol Abuse & Alcoholism (R01AA029819): Subaward **\$1,651,265**/\$2,753,743

Project Leader: 35% (PI: J. Frank Wharam)

- ❖ This project will study the impact of high-deductible health plans and the COVID-19 pandemic on alcohol use disorder treatment access, outcomes, and disparities.

2021~2025: *Can the Medicare Quality Payment Program Incentivize Evidence-Based Treatment of Depression and Anxiety Disorders by Primary Care Providers?*

by National Institute of Mental Health (R01MH125820): Subaward **\$296,746**/\$1,355,482

Site-Principal Investigator: 25% (PI: Kenton J. Johnston)

- ❖ This project will evaluate the effect of Quality Payment Program financial incentives on access to, and outcome of, evidence-based treatment by primary care physicians for depression and anxiety disorders.

PREVIOUS FUNDING

2021~2021: *Racial Disparities in Opioid Tapering and the Impact of State Opioid Policies.*

by Harvard Medical School & Harvard Pilgrim Health Care Institute Faculty Grant

Principal Investigator

- ❖ This project elucidates the racial/ethnic differences in appropriate and inappropriate opioid tapers among commercial plan enrollees who are prescribed long-term opioid therapy and the opioid-related state policy effects on racial/ethnic disparities.

2020~2022: *Impact of Opioid Prescribing Policies for Pain Management in Medicare.*

by Harvard Medical School & Harvard Pilgrim Health Care Institute Faculty Grant

Principal Investigator

- ❖ This project generates timely knowledge about whether the state prescription limit laws and Medicare opioid safety edits have alleviated excessive opioid prescribing, while ensuring appropriate pain management in the elderly Medicare population.

2020~2022: *RECOVER: Understanding COVID-19 Impacts on Health Outcomes and Equity in the New England Region.*

by *Harvard Pilgrim Health Care Institute*

Co-Investigator (MPIs: Alison A. Galbraith, J. Frank Wharam)

- ❖ The project seeks to determine the impact of the COVID-19 pandemic on health insurance enrollment, health services utilization, and health outcomes among Harvard Pilgrim Health Care members.

2020~2021: *State-level Barriers and Facilitators for Evidence-Based Treatment of Opioid Use Disorder Among the Uninsured Population.*

by *Laura & John Arnold Foundation*

Site-Principal Investigator (PI: Richard Grucza)

- ❖ This project uses qualitative, semi-quantitative and quantitative methods to examine state policies and practices governing opioid use disorder treatment for uninsured individuals.

2016~2020: *Center for Rural Health Research.*

by *Health Resources and Services Administration (U01CRH30041)*

Co-Investigator (PI: Tyrone F. Borders)

- ❖ This project aims to examine the effects of Medicaid expansion on insurance coverage and access to substance abuse treatment and the rural-urban differences in policy effects.

UNFUNDED/PENDING PROPOSALS

2022~2026: *Impact of State and Local Paid Sick Leave Mandates on Disparities in Emergency Department Use and Costs in the Working-Age Population.*

Submitted to *National Institute on Aging (R01AG080479)*

Principal Investigator

- ❖ This project will capitalize on the place-based nature of state and local paid sick leave legislation and spatial patterns of racial/ethnic gaps in paid sick leave access and excess emergency department use to create actionable knowledge about the cost-saving and disparity-narrowing potentials of mandatory paid sick leave in an evolving pre- and post-pandemic landscape.

SELECTED CONFERENCE PRESENTATIONS

AcademyHealth Annual Research Meeting:

2023: "Evaluation of a Massachusetts Opioid Prescribing Law Among Post-Operative Orthopedic Patients."

2022: "State Mandatory Paid Sick Leave Associated with Declined Emergency Department Use."

2020: "Adding a Claims-Based Frailty Index to Medicare's Risk Adjustment Model Can Improve Prediction of Annual Medicare Costs and Enable Equitable Reimbursement."

2018: "The Impact of Medicaid Expansion on Preventable Hospitalizations and Spending."

2016: "Prescription Drug Monitoring Program Mandates Associated with Reduced Opioid Use by Medicaid Enrollees."

2015: "Effect of Medicaid Expansions for Low-Income Adults on Health Coverage for and Access to Mental Health Care."

2013: "Medicaid Expansion, Substance Abuse Treatment Use, and Crime Reduction."

American Society of Health Economists (ASHEcon) Biennial/Annual Conference:

2020: "Recreational Cannabis Laws and Opioid-Related Emergency Department Visit Rates."

2016: "Estimating the Implications of Medication-Assisted Treatment for Opioid Use."

2014: "Fighting Crime through Treatment: Evidence from Public Insurance Expansions and Health Insurance Parity Mandates for Substance Abuse Treatment."

SERVICES

AD-HOC REVIEWER

Addiction

Health Affairs, Health Affairs Scholar

Health Economics

Health Services Research

JAMA, JAMA Internal Medicine, JAMA Health Forum, JAMA Pediatrics, JAMA Psychiatry

Journal of Health Economics

The Journal of Law & Economics

TEACHING & MENTORSHIP

COURSE INSTRUCTOR

2016~2019 "*Health Economics.*" University of Kentucky

2017~2018 "*Doctoral Seminar in Research Methods.*" University of Kentucky (Co-Instructor)

2014 "*Advanced Quantitative Methods I.*" Emory University (Co-Instructor)

POSTDOCTORAL PRIMARY ADVISOR

Bryant Shuey, Harvard Medical School Fellowship in General Medicine and Primary Care

❖ Assistant Professor of Medicine, University of Pittsburg School of Medicine

Jiebing Wen, Harvard Pilgrim Health Care Institute Thomas O. Pyle Fellowship

❖ Research Associate, Weill Medical College of Cornell University

POSTDOCTORAL CO-ADVISOR

Yanlei Ma, Harvard Pilgrim Health Care Institute Thomas O. Pyle Fellowship

❖ Research Fellow, Harvard T.H. Chan School of Public Health

DOCTORAL CO-ADVISOR

D. Keith Branham, University of Kentucky College of Public Health, Dr.Ph.

❖ Senior Research Analyst, U.S. Department of Health and Human Services

Lava Timsina, University of Kentucky College of Public Health, Ph.D.

❖ Assistant Professor of Surgery and Associate Director for the Center for Outcomes Research in Surgery, Indiana University School of Medicine

Katherine Toran, University of Kentucky Gatton College of Business and Economics, Ph.D.

❖ Economist, Food and Drug Administration Office of Policy, Legislation, International Affairs

Jiebing Wen, University of Kentucky Martin School of Public Policy & Administration, Ph.D.

❖ Postdoctoral Scholar, Harvard Pilgrim Health Care Institute

❖ Research Associate, Weill Medical College of Cornell University